KLRS KLRS
Company Profile ↓Company Overview
KLRS (KLRS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.02.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +62.40% |
| 6 Months: | -54.16% |
| 3 Months: | -20.94% |
| 1 Month: | -13.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)51.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 61.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -5.95M | -8.48M | -9.84M | -12.15M | -23.90M | -30.86M | -37.66M | -45.50M | -43.19M | -44.62M | -42.95M | -43.23M | -47.30M | -46.96M | -2.56M | -4.19M | -37.85M | -10.35M | -12.26M | -12.74M | -11.83M |
| Net Income | -2.52M | -5.30M | -7.27M | -9.34M | -11.63M | -23.61M | -30.92M | -37.59M | -45.51M | -43.86M | -44.64M | -42.07M | -41.18M | -45.27M | -44.27M | -3.41M | -5.65M | -38.08M | -10.20M | -11.35M | -11.89M | -10.86M |
| Diluted EPS | - | - | - | - | - | - | - | -0.60 | -0.72 | -0.69 | -0.69 | -0.50 | -0.44 | -0.48 | -0.39 | -2.60 | -4.26 | -28.16 | -2.52 | -0.61 | -0.64 | -0.46 |
| R&D Expense | - | 2.75M | 5.66M | 6.84M | 8.88M | 17.18M | 20.39M | 25.68M | 33.06M | 29.07M | 31.38M | 30.00M | 30.72M | 34.82M | 34.16M | 1.96M | 3.21M | 36.02M | 6.03M | 8.44M | 9.13M | 7.57M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 165.00K | - | - | - | - | - | - |
| Operating Income | -26.70M | -71.31M | -169.82M | -171.20M | -199.90M | -51.73M | -46.15M |
| Net Income | -23.84M | -69.78M | -171.96M | -168.71M | -190.42M | -69.17M | -43.44M |
| Diluted EPS | - | - | -2.74 | -2.20 | -42.09 | -51.77 | -2.85 |
| R&D Expense | 16.25M | 49.66M | 120.73M | 118.87M | 133.07M | 45.04M | 30.75M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 139.42M | 370.82M | 286.59M | 277.08M | 190.80M | 6.16M | 121.74M |
| Total Equity | -30.62M | -51.50M | 353.06M | 225.27M | 224.52M | -45.02M | -96.62M | 78.81M |
| Cash & Equivalents | - | 61.08M | 122.66M | 201.66M | 106.09M | 90.12M | 1.64M | 98.05M |
| Total Liabilities | - | 17.80M | 17.76M | 61.33M | 52.56M | 45.02M | 56.78M | 42.92M |
| Current Liabilities | - | 9.11M | 12.29M | 37.85M | 24.34M | 28.37M | 24.70M | 9.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.16M | -60.81M | -106.32M | -142.05M | -124.45M | -20.67M | -38.37M |
| Investing Cash Flow | -64.64M | -169.50M | 185.98M | -80.48M | 37.98M | 95.00M | -19.72M |
| Financing Cash Flow | 120.92M | 291.98M | 232.00K | 126.96M | 70.50M | 19.14M | 155.01M |
| Capital Expenditure | -339.00K | -235.00K | -26.00K | - | - | - | -200.00K |
| Free Cash Flow | -20.49M | -61.05M | -106.34M | - | - | - | -38.57M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -16,182.4% | - | - | - | - | - | - |
| Net Margin % | -14,447.9% | - | - | - | - | - | - |
| ROE % | 46.3% | -19.8% | -76.3% | -75.1% | 423.0% | 71.6% | -55.1% |
| ROCE % | -20.5% | -19.9% | -68.3% | -67.7% | -123.1% | 279.0% | -41.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KLRS
KLRS Stock Dips As Traders React To Volatile Intraday Spike - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNal9kS0ZqbWxZRDZYclgtM3g3ZHRLR0JLZG1wZk1XTldVSFpNdTgxam45Ykx4VlhCZU5GaVlVUEl1cDJHb29GSlI2Q3JQLTJaNzNKaHc4X3MzQTVCOE9hRWN2V0lZbHphcmRSZjV1QkVCVERGcE1YUVpQaUFmZDg2dE1fYw?oc=5" targe…
Price to sales forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPeVhWR0F4Ym5rM2JTMDJIeWFRVTRkVkt3MF9wb1NLMlhBWFRjZ2FlNjBOOVM4WXdrZ2VxUlBKRXdQWVlUYTZiLXpybGlnYTBSNlFfbXdrX19UM3NWbG1KZkhuZFRiVWw0NUNLa3kyT2hyM3pNUzVFakFBdzRRMjlZU29RY3ZDbzZmM3NOYl…
KLRS|Kalaris Therapeutics Inc|Price:3.510|Chg%:+0.030 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9yUnRYLVVvRmFQME5jWWV2Skw0R0pXS3VwdEF3MEJnc0ZORng5dWJzZ0dSSHVkY0I1YUc5Q1dXbjA0eTJSOHpkczJoRG5NTUpjaTM1eEhnbUJhb1ZvaEhvOGdvRDQ3NUxyN0RZWWFn?oc=5" target="_blank">KLRS|Kalaris Therap…
Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE11LW1MbUx2cFVHMDdRLTFPUjFxMjBoaWR4MU9SYWRhOUZuWEdPdXhiYzQzdkZULVdDSlBwXy1RRDBNRUhMbTAydEVRM3poSFhzaWc?oc=5" target="_blank">Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quot…
Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOS3k3T0xVbmRhUVMzWXVZYi1EZFlTeVVoV1R6WDVjcG83ZFZnUHRad3htZVpKUmNCVVVqaG4zV01ZUE5TbmVDZ2RyNHFZOEF0OUhUU0xTSmsySVB2RDJTQWNJZ1hNVUE2UkozR0NxVzNCbVl4WTFwZzRteHFFU2RmSjJORVA5OUhBS3VfdF…
Kalaris names biotech veteran Laurie Keating to its board - Stock Titan
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOZFkzTm5ySmJaWGQ5MzQwejF6cnQtc25MMFZHZUgyeklSdDF3cmVxajRET1JjZlQ1RzI2bUkyMllDckx2WFJLdmlaOWVFRGNYMzM5YkxZMkxyNzRJaGU5VlM3eGpRUjNqQnc2cllNSlB5ajdOS3VCMzJaNGlKTWgzSnpCMjZnNWMzNWI0LT…
KLRS — Frequently Asked Questions
What is the current share price of KLRS?
As of 2026-08-05 17:25 PDT, KLRS trades at $4.19 on NASDAQ/NYSE. Its 52-week range is $2.27 to $10.98.
What is the P/E ratio of KLRS?
KLRS trades at a trailing price-to-earnings (P/E) ratio of -1.47.
What is the return on equity (ROE) of KLRS?
KLRS has a return on equity (ROE) of -55.11%. Its return on capital employed (ROCE) is -41.20%.
Is KLRS a good stock to buy?
This page provides a data-driven analysis of KLRS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.